How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
Stefania Morganti(Broad Institute), Carmen Criscitiello(University of Milan), Giuseppe Curigliano(European Institute of Oncology), Antonio Giordano(University of Siena), Giampaolo Bianchini(Vita-Salute San Raffaele University), Mario Giuliano(Regione Campania)
Cited by 11
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k